Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of Pembrolizumab (KEYTRUDA) in Combination With REOLYSIN (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Next Previous
Trial Profile

A Phase 1b Study of Pembrolizumab (KEYTRUDA) in Combination With REOLYSIN (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pelareorep (Primary) ; Pembrolizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan
  • Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
  • Focus Adverse reactions
  • Sponsors Oncolytics Biotech

Most Recent Events

  • 10 Jul 2025 According to an Oncolytics media release, the company will host a key opinion leader (KOL) webinar on Tuesday, July 22, 2025, at 1:00 p.m. ET to discuss pelareorep in metastatic pancreatic ductal adenocarcinoma (mPDAC) and other gastrointestinal cancers.
  • 06 Nov 2019 Results presented in the Oncolytics Biotech Media Release.
  • 06 Nov 2019 Results assessing efficacy and safety of pembrolizumab in combination with pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma, published in the Clinical Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top